Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1176-1183

  Brooks, David P ^a,c   Valente, Maurizio ^b   Petrone, Giuseppe ^b   Depalma, P Dennis ^a   Sbacchi, Massimo ^b   Clarke, Geoffrey D ^b  

^a SmithKline Beecham Pharmaceutical ^*  (United States)

^b SmithKline Beecham SpA   (Italy)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KAPPA OPIATE RECEPTOR; MOZAVAPTAN; NIRAVOLINE; OPIATE AGONIST; SB 215519; SB 215520; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

ARTICLE; ATAXIA; CONTROLLED STUDY; DIURESIS; DOG; DRUG EFFECT; FEMALE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM RETENTION;

ANIMALS; BENZAZEPINES; BENZENEACETAMIDES; DIURESIS; DOGS; FEMALE; MALE; PIPERIDINES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, VASOPRESSIN; WATER;

EID: 0030904374     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ALBRIGHTSON-WINSLOW, C. R., CALDWELL, N., BROOKS, D. P., HUFFMAN, W., STASSEN, F. L. AND KINTER, L. B.: Cyclooxygenase inhibition unmasks the full antidiuretic activity of the vasopressin antagonist, SK&F 101926, in dogs. J. Pharmacol. Exp. Ther. 249: 66-371, 1989.
2. ALLISON, N., ALBRIGHTSON-WINSLOW, C. R., BROOKS, D. P., STASSEN, F. L., HUFFMAN, W. F., STOTE, R. M. AND KINTER, L. B.: Species heterogeneity and antidiuretic hormone antagonists: what are the predictors? In Vasopressin, Cellular and Integrative Functions, ed. BY A. W. Cowley, J. F. Liard and D. Aussiello, pp. 207-214, Raven Press, New York, 1988.
3. BOSCH-MARCE, M., JIMENEZ, W., ANGELI, P., LEIVAS, A., CLARIA, J., GRAZIOTTO, A., ARROYO, V., RIVERA, F. AND RODES, J.: Aquaretic effect of the kappa opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 109: 217-223, 1995.
4. BROOKS, D. P.: Development of selective water diuretics: Potential molecular targets. Pharmacol. Commun. 8: 75-80, 1996.
5. 2-adrenoceptors is species specific. Am. J. Physiol. 261: R1242-R1246, 1991.
6. BROOKS, D. P., GIARDINA, G., GELLAI, M., DONDIO, G., EDWARDS, R. M., PETRONE, G. P., DEPALMA, P. D., SBACCHI, M., JUGUS, M., MISIANO, P., WANG, Y-X. AND CLARKE, G. D.: Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J. Pharmacol. Exp. Ther. 266: 164-171, 1993.
7. BROOKS, D. P., KOSTER, P. F., ALBRIGHTSON-WINSLOW, C. R., STASSEN, F. L., HUFFMAN, W. AND KINTER, L. B.: SK&F 105494 is a potent vasopressin antidiuretic antagonist in the rhesus monkey (Macaca mulatta). J. Pharmacol. Exp. Ther. 245: 211-215, 1988.
8. CALDWELL, N., BRICKSON, B., KINTER, L. B., BROOKS, D. P., HUFFMAN, W. F., STASSEN, F. L. AND ALBRIGHTSON-WINSLOW, C.: SK&F 105494: A potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs. J. Pharmacol. Exp. Ther. 247: 897-901, 1988.
9. 50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
10. DIONNE, R. A., DOBBINS, K. R. AND HARGREAVES, K. M.: Evaluation of a kappa opioid agonist, spiradolone, in comparison to morphine and placebo in the oral surgery model. Clin. Pharmacol. Ther. 49: 183, 1991.
11. HAYES, A. G. AND TYERS, M. B.: Determination of receptors that mediate opioid side effects in the mouse. Br. J. Pharmacol. 79: 731-736, 1983.
12. ILSON, B. E., JORKASKY, D. K., ALDINS, Z. AND STOTE, R. M.: SK&F 105494 is antidiuretic in man. Kidney Int. 37: 583, 1990.
13. IWAMOTO, E. T.: Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J. Pharmacol. Exp. Ther. 217: 451-460, 1981.
14. LEANDER, J. D.: A kappa opioid effect: increased urination in the rat. J Pharmacol. Exp. Ther. 224: 89-94, 1983.
15. KAPUSTA, D. R. AND OBIH, J. C.: Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves. J. Pharmacol. Exp. Ther. 267: 197-204, 1993.
16. KINTER, L. B., CHURCHILL, S., STASSEN, F. L., MOORE, M. AND HUFFMAN, W.: Characterization and mechanism of action of vasopressin antagonists in squirrel monkeys (Saimiri sciureus). J. Pharmacol. Exp. Ther. 241: 797-803, 1987.
17. KOSTERLITZ, H. W. PATERSON, S. J. AND ROBSON, L. E.: Characterization of the kappa subtype of the opioid receptor in the guinea pig brain. Br. J. Pharmacol. 73: 939-949, 1981.
18. MANNING, M., LAMMEK, B., KOLODZIEJCZYK, A. M., SETO, J. AND SAWYER, W.: Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine vasopressin. J. Med. Chem. 24: 701-706, 1981.
19. MUNSON, P. J. AND RODBARD, D.: Ligand, a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 220-239, 1980.
20. OHNISHI, A., ORITA, Y., OKAHARA, R., FUJIHARA, H., INOUE, T., YAMAMURA, Y., YABUUCHI, Y. AND TANAKA, T.: A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest, 92: 2653-2659, 1993.
21. OHNISHI, A., MIHARA, M., YASUDA, S., TOMONO, Y., HASEGAWA, J. AND TANAKA, T.: Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J. Pharmacol. Exp. Ther. 270: 42-347, 1994.
22. PETERS, G. AND GAYLOR, S.: Human central nervous system (CNS) effects of a elective kappa opioid agonist. Clin. Pharmacol. 45: 130, 1989.
23. PETRILLO, P., LA REGINA, A., SBACCHI, M., TAVANI, T., ROBSON, L. E. AND KOSTERLITZ, H. W.: Regional variations in binding capacities at mu, delta and kappa opioid sites in membrane suspensions from rabbit brain. Eur. J. Pharmacol. 166: 213-217, 1989.
24. REECE, P. A., SEDMAN, A. J., ROSE, S., WRIGHT, D. S., DAWKINS, R. AND RAJAGOPALAN, R.: Diuretic effects, pharmacokinetics and safety of a new centrally acting kappa opioid agonist (CI-977) in humans. J. Clin. Pharmacol. 34: 1126-1132, 1994.
25. RIMOY, G. H., BHASKAR, N. K., WEIGHT, D. M. AND RUBIN, P. C.: Mechanism of diuretic action of spiradoline (U-62066E): A kappa opioid receptor agonist in the human. Br. J. Clin. Pharmacol. 32: 611-615, 1991.
26. ROSSI, N. F. AND BROOKS, D. P.: Kappa opioid agonist inhibition of osmotically induced AVP release: preferential action at hypothalamic sites. Am. J. Physiol. 270: E367-E372, 1996.
27. RUFFOLO, R. R., JR., BROOKS, D. P., HUFFMAN, W. F. AND POSTE, G.: From vasopressin antagonist to agonist: A saga of surprise! Drug News Perspect. 4: 217-222, 1991.
28. SAWYER, W. H., PANG, P. K. T., SETO, J., MCENROE, M., LAMMEK, B. AND MANNING, M.: Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 212: 49-51, 1981.
29. SBACCHI, M. AND CLARKE, G. D.: BRL 52537: A novel, highly potent kappa opioid receptor ligand. In New Leads in Opioid Research, Excerpta Medica, International Congress Series, 914: 211-212, 1990.
30. SINNASSAMY, P., SULTAN, E. AND BICHET, D. G.: Aquaretic effect of Niravoline (RU 51599) a kappa opioid agonist in healthy volunteers. J. Am. Soc. Nephrol. 5: 373, 1994.
31. 3H-EKC binding by opioids in rat kidney: A correlate to diuretic activity. Life Sci. 36: 2189-2193, 1985.
32. SLIZGI, G. R. AND LUDENS, J. H.: Role of ADH in ethylketocyclazocine-induced diuresis: studies in the Brattleboro rat. Life Sci. 38: 2437-2440, 1986.
33. STASSEN, F. L., BRYAN, W., GROSS, M., KAVANAGH, B., SHUE, D., SULAT, L., WIEBELHAUS, V., YIM, N. AND KINTER, L. B.: Critical differences between species in the in vivo and in vitro responses to antidiuretic hormone antagonists. Prog. Brain Res. 60: 395-403, 1983.
34. SUTTERS, K. A., MIASKOWSKI, C., TAIWO, Y. O. AND LEVINE, J. D.: Analgesic synergy and improved motor function produced by combinations of mu-delta and mu-kappa opioids. Brain Res. 530: 290-294, 1990.
35. 3H]-bremazocine in guinea pig brain: Evidence of multiplicity of the k-opioid receptors. Can. J. Physiol. Pharmacol. 67: 1336-1344, 1988.
36. VECCHIETTI, V., COLLE, R., GIARDINA, G., DONDIO, G. AND LEURINI, L.: N-Acylsubstituted azacyclic compounds, processes for their preparation and their use as pharmaceuticals. British Patent Applications no. 8926561.5 (Nov. 24, 1989) and no. 9003137.8 (Feb. 12, 1990). International Patent WO 91/08206 (June 13, 1991). U.S. Patent 5,322,848 (June 21, 1994).
37. WANG, Y-X., CLARKE, G. D., SBACCHI, M., PETRONE, G. AND BROOKS, D. P.: Contribution of alpha-2 adrenoceptors to kappa opioid agonist-induced water diuresis in the rat. J. Pharmacol. Exp. Ther. 270: 244-249, 1994.
38. YAMADA, K., IMAI, M. AND YOSHIDA, S.: Mechanism of diuretic action of U-62,066E, a kappa opioid receptor agonist. Eur. J. Pharmacol. 160: 229-237, 1989.
39. YAMAMURA, Y., OGAWA, H., YAMASHITA, H., CHIHARA, T., MIYAMOTO, H., NAKAMURA, S., ONOGAWA, T., YAMASHITA, T., HOSOKAWA, T., MORI, T., TOMINAGA, M. AND YABUUCHI, Y.: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105: 787-791, 1992.
40. 2 opioid receptors. Proc. Natl. Acad. Sci. U.S.A. 85: 4061-4065, 1988.